vimarsana.com

Page 31 - மன இறுக்கம் ஸ்பெக்ட்ரம் கோளாறு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

26th year for Run for Autism, formerly Kilbride Classic

Listen to this article The Run for Autism will be on Father’s Day starting at Cobb Park at 8 a.m., according to information provided. It will benefit people with Autism. The Run can be done as a 5K Run, 2 Mile Walk, or a 200 Yard Dash for Children. For completing the race, those who registered by June 6 will receive a T-shirt with a design created by an artist with Autism. Registration is online and LIVE at http://www.merchantstreetartgallery.org. Monies raised at this event will stay local and will go toward workshops, classes and other opportunities/services for those who have an Autism Spectrum Disorder (and their families) through the Merchant Street Art Gallery of Artists with Autism.

Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Highlights

Zynerba Pharmaceuticals Inc says its fully funded well into 2024; lays out plans for Zygel RECONNECT trial for Fragile X patients

The company reported that cash on hand increased 57% year-over-year from $59.2 million to $93.1 million The RECONNECT trial, planned for the third quarter, will enroll around 200 children and adolescents with Fragile X Syndrome Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) (FRA:6ZY) told investors it believes it has sufficient cash to fund its operations well into the first half of 2024 after the company reported cash and equivalents of $93.1 million on hand at the end of the first quarter.  In a business update for the three months ended March 31, the company reported that cash on hand increased 57% year-over-year from $59.2 million at the end of the first quarter last year. 

STALICLA SA: STALICLA Appoints Baltazar Gomez-Mancilla, MD, PhD, as Chief Medical Officer

STALICLA SA: STALICLA Appoints Baltazar Gomez-Mancilla, MD, PhD, as Chief Medical Officer Appointment will benefit STALICLA s robust drug discovery platform and pipeline development STALICLA SA, a Swiss clinical stage biopharmaceutical company leading omics-based precision medicine drug development for patients with neurodevelopmental disorders (NDDs), announced today the appointment of Baltazar Gomez-Mancilla, MD, PhD, to the position of Chief Medical Officer. Dr. Gomez-Mancilla, whose clinical neuroscience leadership includes more than 25 years of experience in the pharmaceutical industry, will help advance clinical trials leveraging the deployment and application of STALICLA s first-in-class precision drug discovery platform DEPI, with an initial application in Autism Spectrum Disorder (ASD). Joining a world-class team of 26 seasoned drug developers, clinicians, data scientists and computational biologists, Dr. Gomez-Mancilla brings invaluable insight from previous roles that in

Is Asperger s Syndrome Named After a Nazi Enabler?

Context While the full extent of Hans Asperger s collaboration with the Nazis remains contested, documented evidence exists that he referred children to the infamous Am Spiegelgrund clinic; it is unlikely that he was unaware of the fact this clinic practiced child euthanasia under the Nazi s Aktion T4 program. Origin In 1981, English psychiatrist Lorna Wing proposed the term “Asperger’s syndrome” as a syndrome in which individuals exhibited some symptoms of autism but did not fit that diagnosis as it was understood at the time. Wing chose that name as a reference to Austrian psychiatrist Hans Asperger, whose case reports Wing used to define the syndrome.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.